Financing Supports Planned US Trial of Lecigon for Advanced Parkinson’s

Financing Supports Planned US Trial of Lecigon for Advanced Parkinson’s

308142

Financing Supports Planned US Trial of Lecigon for Advanced Parkinson’s

Intrance Medical Systems has raised $8 million to support a planned U.S. clinical trial of its fixed-dose combination of levodopa, carbidopa, and entacapone in advanced Parkinson’s disease patients. The combo therapy, originally developed by Lobsor Pharmaceuticals and sold under the name Lecigon in Nordic countries —  Denmark, Finland, Iceland, Norway and Sweden, and their associated territories — and in certain other European countries. The company, a subsidiary of Sweden-based Intrance Holdings, is planning to open a pivotal U.S. study next year, it stated in a press…

You must be logged in to read/download the full post.